, Synthèse -Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre, 1990.

D. Sur,

. Santé-publique-française, Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018 -Tumeurs solides : Étude à partir des registres des cancers du réseau Francim

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: A Cancer Journal for Clinicians. nov, vol.68, issue.6, pp.394-424, 2018.

A. Dhellemmes, C. Melan, and F. Sordes, Qualité de vie des patients atteints de cancer traités à domicile : étude comparative des différentes voies d'administration de la chimiothérapie, Bulletin du Cancer. déc, vol.106, issue.12, pp.1124-1155, 2019.

, Développement des anticancéreux oraux -Projections à court, moyen et long termes, 2016.

. Ansm, Référentiel des ATU nominatives

D. Sur,

. Ansm, Point d'information -L'ANSM facilite la mise à disposition de nouvelles thérapies en cancérologie, 2014.

. Ansm, Point d'information -L'ANSM met en place un dispositif accéléré d'autorisation d'essais cliniques (Fast Track), 2018.

D. Sur,

M. Krohe, D. Eek, I. Mazar, A. Horsfield, F. Pompilus et al., Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature, PPA. août, vol.10, pp.1609-1630, 2016.

, Plan Cancer, 2014.

D. Sur,

J. M. Solomon, V. B. Ajewole, A. M. Schneider, M. Sharma, and E. H. Bernicker, Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center, J Oncol Pharm Pract, vol.25, issue.7, pp.1564-1573, 2019.

M. Sharp-&-dohme and . Corp, A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

, Les thérapies ciblées dans le traitement du cancer en 2015 -État des lieux et enjeux

D. Tadic, I. B. Spasojevic, Z. I. Tomasevic, and S. D. Dejanovic, Oral administration of antineoplastic agents: the challenges for healthcare professionals, J BUON. juin, vol.20, issue.3, pp.690-698, 2015.

G. Liu, E. Franssen, M. I. Fitch, and E. Warner, Patient preferences for oral versus intravenous palliative chemotherapy, JCO. janv, vol.15, issue.1, pp.110-115, 1997.

C. Catania, F. Didier, M. E. Leon, A. Sbanotto, L. Mariani et al., Perception that Oral Anticancer Treatments are Less Efficacious: Development of a Questionnaire to Assess the Possible Prejudices of Patients with Cancer, Breast Cancer Res Treat. août, vol.92, issue.3, pp.265-72, 2005.

, La chimiothérapie orale du cancer en 2014 -Notes d'analyses, 2015.

L. Lay, K. Myon, E. Hill, S. Riou-franca, L. Scott et al., Comparative costminimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system, Eur J Health Econ. juin, vol.8, issue.2, pp.145-51, 2007.

, Les cancers en France en 2017-L'essentiel des faits et chiffres, 2017.

C. Morin and D. Rochefort, Thérapies orales en oncologie : comment s'y retrouver ? Quebec Pharmacie, Aout, p.27, 2018.

T. Müller, Typical Medication Errors in Oncology: Analysis and Prevention Strategies, Oncol Res Treat, vol.26, issue.6, pp.539-583, 2003.

, Données globales d'épidémiologie des cancers -Epidémiologie des cancers, 2019.

S. Krikorian, S. Pories, G. Tataronis, T. Caughey, K. Chervinsky et al., Adherence to oral chemotherapy: Challenges and opportunities, J Oncol Pharm Pract, vol.25, issue.7, pp.1590-1598, 2019.

F. Bassan, F. Peter, B. Houbre, M. J. Brennstuhl, M. Costantini et al., Adherence to oral antineoplastic agents by cancer patients: definition and literature review: Adherence to oral treatment in cancer, Eur J Cancer Care (Engl). janv, vol.23, issue.1, pp.22-35, 2014.

, Améliorer l'observance : Traiter mieux et moins cher, 2014.

J. Allen and S. Williamson, Over compliance with capecitabine oral chemotherapy, Int J Clin Pharm. avr, vol.36, issue.2, pp.271-274, 2014.

B. Glintborg, S. E. Andersen, and K. Dalhoff, Insufficient communication about medication use at the interface between hospital and primary care. Qual Saf Health Care, févr, vol.16, issue.1, pp.34-43, 2007.

L. Hammond, E. Marsden, N. O'hanlon, F. King, M. C. Henman et al., Identification of risks associated with the prescribing and dispensing of oral anticancer medicines in Ireland, Int J Clin Pharm. déc, vol.34, issue.6, pp.893-901, 2012.

R. M. Tamblyn, P. J. Mcleod, M. Abrahamowicz, and R. Laprise, Do too many cooks spoil the broth? Multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations, CMAJ. 15 avr, vol.154, issue.8, pp.1177-84, 1996.

L. H. Nazer, F. Hawari, A. , and T. , Adverse Drug Events in Critically Ill Patients With Cancer: Incidence, Characteristics, and Outcomes, Journal of Pharmacy Practice. avr, vol.27, issue.2, pp.208-221, 2014.

G. Riu-viladoms, E. Martín, M. T. Martín-conde, and N. Creus, Drug interactions with oral antineoplastic drugs: The role of the pharmacist, European Journal of Cancer Care, vol.28, issue.1, p.12944, 2019.

M. Huet, Les plantes médicinales chez les malades atteints de cancers : pratiques courantes et éléments de leur évaluation, Bulletin du Cancer. 1 mai, vol.100, issue.5, pp.485-95, 2013.

V. Escudero-vilaplana, A. Ribed, R. M. Romero-jimenez, A. Herranz-alonso, and M. Sanjurjo-saez, Pharmacotherapy follow-up of key points in the safety of oral antineoplastic agents, Eur J Cancer Care. mai, vol.26, issue.3, p.12463, 2017.

A. Bayraktar-ekincioglu, K. Demirkan, B. Keskin, O. Aslantas, and E. Ozdemir, Potential drug interactions and side effects in an outpatient oncology clinic: a retrospective descriptive study, Eur J Hosp Pharm. août, vol.21, issue.4, pp.216-237, 2014.

J. Aisner, Overview of the changing paradigm in cancer treatment: Oral chemotherapy, American Journal of Health-System Pharmacy. 1 mai, vol.64, pp.4-7, 2007.

M. L. Voll, K. D. Yap, W. E. Terpstra, and M. Crul, Potential drug-drug interactions between anticancer agents and community pharmacy dispensed drugs, Pharm World Sci, vol.32, issue.5, pp.575-80, 2010.

B. Allenet, M. Juste, C. Mouchoux, R. Collomp, X. Pourrat et al., De la dispensation au plan pharmaceutique personnalisé : vers un modèle intégratif de pharmacie clinique, Le Pharmacien Hospitalier et Clinicien. mars, vol.54, issue.1, pp.56-63, 2019.

, février 2016 relative à l'appel à projet de mise en oeuvre de la pharmacie clinique en établissement de santé

D. Sur,

D. Serin, S. Adnot, A. , and C. , Compte rendu du congrés SFSPM 2018 -Congrès de la Société Française de Sénologie et de Pathologie Mammaire, vol.18

. Oncologie, , vol.20, pp.145-189, 2018.

J. Officiel-de-la-république-française, Ordonnance n° 2016-1729 du 15 décembre 2016 relative aux pharmacies à usage intérieur -Légifrance, 2016.

D. Sur,

S. Occhipinti, E. Petit-jean, F. Pinguet, C. Beaupin, M. Daouphars et al., Implication du pharmacien dans l'accompagnement des patients sous anticancéreux oraux : état des lieux dans les centres de lutte contre le cancer (CLCC), Bulletin du Cancer. sept, vol.104, issue.9, pp.727-761, 2017.

B. Loulière, I. Alquier, S. Briançon, N. Thilly, F. Empereur et al., Initiative des HIGH 5s -Rapport d'expérimentation sur la mise en oeuvre de la conciliation des traitements médicamenteux par neuf établissements de santé français, vol.125, 2015.

, Mettre en oeuvre la conciliation des traitements médicamenteux en établissement de santé, HAS, 2018.

E. Dufay, S. Morice, A. Dony, T. Baum, S. Doerper et al., The clinical impact of medication reconciliation on admission to a French hospital: a prospective observational study, Eur J Hosp Pharm. juill, vol.23, issue.4, pp.207-219, 2016.

K. M. Gleason, M. R. Mcdaniel, J. Feinglass, D. W. Baker, L. Lindquist et al., Results of the Medications At Transitions and Clinical Handoffs (MATCH) Study: An Analysis of Medication Reconciliation Errors and Risk Factors at Hospital Admission, J GEN INTERN MED. mai, vol.25, issue.5, pp.441-448, 2010.

E. Dufay, T. Baum, S. Doerper, E. Conrard, A. Dony et al., Conciliation des traitements médicamenteux : détecter, intercepter et corriger les erreurs médicamenteuses à l'admission des patients hospitalisés, Risques et Qualités, vol.8, issue.2, pp.130-138, 2011.

S. Rennke, O. K. Nguyen, M. H. Shoeb, Y. Magan, R. M. Wachter et al., Hospital-Initiated Transitional Care Interventions as a Patient Safety Strategy: A Systematic Review, Ann Intern Med. 5 mars, vol.158, issue.5, pp.433-474, 2013.

B. W. Jack, V. K. Chetty, D. Anthony, J. L. Greenwald, G. M. Sanchez et al., A Reengineered Hospital Discharge Program to Decrease Rehospitalization, Ann Intern Med. 3 févr, vol.150, issue.3, pp.178-87, 2009.

L. Alix, M. Dumay, B. Cador-rousseau, H. Gilardi, B. Hue et al., Conciliation médicamenteuse avec remise d'une fiche de conciliation de sortie dans un service de Médecine Interne : évaluation de la perception des médecins généralistes, La Revue de Médecine Interne. juin, vol.39, issue.6, pp.393-402, 2018.

H. Lehmann, Un nouveau dispositif d'accompagnement du patient en officine : le « bilan partagé de médication », Annales Pharmaceutiques Françaises. 1 juill, vol.77, issue.4, pp.265-75, 2019.

B. Allenet, D. Cabelguenne, A. Lepelletier, S. Prot-labarthe, C. Mouchoux et al., Le plan pharmaceutique personnalisé et le nouveau modèle de pharmacie clinique, Le Pharmacien Hospitalier et Clinicien. sept, vol.52, issue.3, pp.306-315, 2017.

, Ordre national des pharmaciens. La pharmacie clinique -État des lieux et perspectives d'une discipline en développement

, Les cahiers de l'ordre national des pharmaciens, 2018.

D. Sur,

P. A. Amaral, . Do, A. M. Mendonça-s-de, . Oliveira-dr-de, L. J. Peloso et al., Impact of a medication therapy management service offered to patients in treatment of breast cancer, Braz J Pharm Sci. 26 juill, vol.54, issue.2, p.221, 2018.

A. Whitman, K. Degregory, A. Morris, S. Mohile, and E. Ramsdale, Pharmacist-led medication assessment and deprescribing intervention for older adults with cancer and polypharmacy: a pilot study, Support Care Cancer. déc, vol.26, issue.12, pp.4105-4118, 2018.

G. Nightingale, E. Hajjar, K. Swartz, J. Andrel-sendecki, and A. Chapman, Evaluation of a Pharmacist-Led Medication Assessment Used to Identify Prevalence of and Associations With Polypharmacy and Potentially Inappropriate Medication Use Among Ambulatory Senior Adults With Cancer, JCO. 1 mai, vol.33, issue.13, pp.1453-1462, 2015.

L. Colombo, P. M. Aguiar, T. M. Lima, and S. Storpirtis, The effects of pharmacist interventions on adult outpatients with cancer: A systematic review, J Clin Pharm Ther. août, vol.42, issue.4, pp.414-438, 2017.

E. Petit-jean and B. Pourroy, Recommandations SFPO sur la réalisation de Consultations Pharmaceutiques en oncologie, vol.10, 2017.

M. Babin, C. Folliard, J. Robert, J. Sorrieul, H. Kieffer et al., Consultations pharmaceutiques en oncologie : mise en place, bilan à un an et perspectives, Annales Pharmaceutiques Françaises. sept, vol.77, issue.5, pp.426-460, 2019.

, HAS. Questions/Réponses -Parcours de soins, 2012.

D. Sur,

, Plan cancer, 2003.

D. Sur, , 2003.

, Plan Cancer, 2009.

D. Sur,

A. Pennetier, S. Falcowski, and N. Picard, Parcours de soins d'un patient atteint de cancer, du diagnostic à l'officine, Actualités Pharmaceutiques. oct, vol.57, issue.579, pp.46-55, 2018.

, Organisation des soins en cancérologie -Ref : RECOMGOSK16, 2016.

C. Pinheiro, H. Morel, M. Burgunder, A. Dixmier, J. Barisien et al., Infirmière coordinatrice de soins en oncologie par filière/parcours complexes : expérience en filière thoracique, Revue des Maladies Respiratoires. janv, vol.34, p.196, 2017.

C. Maritaz, N. Gault, C. Roy, F. Tubach, S. Burnel et al., Impact d'une organisation régionale coordonnée pour sécuriser la prise en charge des patients sous anticancéreux oraux : CHIMORAL, une étude comparative, Bulletin du Cancer. sept, vol.106, issue.9, pp.734-780, 2019.

C. M. Alfano, D. K. Mayer, S. Bhatia, J. Maher, J. M. Scott et al., Implementing personalized pathways for cancer follow-up care in the United States: Proceedings from an, Clinical Oncology summit. CA A Cancer J Clin. mai, vol.69, issue.3, pp.234-281, 2019.

A. Becuwe and C. Thebaut, Les impacts des nouvelles technologies sur les systèmes de santé. L'Harmattan, vol.2020, pp.9-13, 2020.

, HAS. Référentiel de bonnes pratiques sur les applications et les objets connectés en santé, 2016.

, Ministère des solidarités et de la santé. Ma Santé 2022 -Dossier de presse, 2018.

D. Sur,

B. Séroussi and J. Bouaud, Applications mobiles de santé et objets connectés : vers une labellisation ? Cordiam Le point sur, vol.6, 2017.

, Avis de la CNEDiMTS -Moovcare Poumon, Disponible sur

O. Mir, M. Ferrua, A. Fourcade, D. Mathivon, A. Duflot-boukobza et al., Intervention combining nurse navigators (NNs) and a mobile application versus standard of care (SOC) in cancer patients (pts) treated with oral anticancer agents (OAA): Results of CapRI, a single-center, randomized phase III trial, JCO, vol.20, issue.2020, pp.2000-2000

D. Maio, M. Gallo, C. Leighl, N. B. Piccirillo, M. C. et al., Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials, JCO. 10 mars, vol.33, issue.8, pp.910-915, 2015.

J. Hippisley-cox and C. Coupland, Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study, BMJ. 16 août, vol.343, issue.aug11, pp.4656-4656, 2011.

A. Carmona-bayonas, P. Jiménez-fonseca, C. Font, F. Fenoy, R. Otero et al., Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index, Br J Cancer, vol.116, issue.8, pp.994-1001, 2017.

M. Sánchez-cánovas, C. Solís, M. De-la-haba, I. Vacas, D. Gómez et al., Optimizing management of the oncological patient with pulmonary embolism: Validation of the epiphany index-PERSEO study, JCO, vol.20, issue.2020, pp.12085-12085

G. T. Gerotziafas, A. Taher, H. Abdel-razeq, E. Aboelnazar, A. C. Spyropoulos et al., A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. The Oncol, vol.22, pp.1222-1253, 2017.

F. Pamoukdjian, E. Liuu, P. Caillet, M. Gisselbrecht, S. Herbaud et al., L'évaluation gériatrique et les scores pronostiques chez le patient âgé atteint de cancer : une aide à la décision thérapeutique ? Bulletin du Cancer, vol.104, pp.946-55, 2017.

P. Soubeyran, C. Bellera, J. Goyard, D. Heitz, H. Cure et al., Validation of the G8 screening tool in geriatric oncology: The ONCODAGE project, JCO. 20 mai, vol.29, pp.9001-9001, 2011.

M. Extermann, I. Boler, R. R. Reich, G. H. Lyman, R. H. Brown et al., Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: CRASH Score, Cancer. 1 juill, vol.118, issue.13, pp.3377-86, 2012.

A. Hurria, K. Togawa, S. G. Mohile, C. Owusu, H. D. Klepin et al., Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study, JCO. 1 sept, vol.29, issue.25, pp.3457-65, 2011.

I. Ortland, M. Ott, M. Kowar, M. Sippel, C. Jaehde et al., Comparing the performance of the CARG and the CRASH score for predicting toxicity in older patients with cancer, Journal of Geriatric Oncology. juill, vol.11, issue.6, pp.997-1005, 2020.

. Aphm, Synopsis de l'essai clinique en cancérologie : DROP-SFPO-2016

, Disponible sur, 2019.

E. Ferrat, E. Paillaud, P. Caillet, M. Laurent, C. Tournigand et al., Performance of Four Frailty Classifications in Older Patients With Cancer: Prospective Elderly Cancer Patients Cohort Study, JCO. 1 mars, vol.35, issue.7, pp.766-77, 2017.

A. Bourmaud, C. Pacaut, A. Melis, F. Tinquaut, N. Magné et al., Is oral chemotherapy prescription safe for patients? A cross-sectional survey, Annals of Oncology. févr, vol.25, issue.2, pp.500-504, 2014.

H. Wildiers, P. Heeren, M. Puts, E. Topinkova, M. Janssen-heijnen et al., International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer, J Clin Oncol. 20 août, vol.32, issue.24, pp.2595-603, 2014.

, Institut National du Cancer. Oncodage -Outil de dépistage gériatrique en oncologie

, Soin et vie des malades, 2012.

M. P. Lawton and E. M. Brody, Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living, The Gerontologist. 1 sept, vol.9, issue.3, pp.179-86, 1969.

J. Jyrkkä, H. Enlund, M. J. Korhonen, R. Sulkava, and S. Hartikainen, Polypharmacy Status as an Indicator of Mortality in an Elderly Population, Drugs & Aging. déc, vol.26, issue.12, pp.1039-1087, 2009.

M. Monégat and C. Sermet, La polymédication : définitions, mesures et enjeux. Questions d'économie de la santé -IRDES, déc, issue.204, p.8, 2014.

H. Bourgeois, V. Tallec, L. D. Decker, O. Dupuis, E. Voog et al., Validation du score Pronopall chez des patients oncogériatriques en situation palliative, Innovations & Thérapeutiques en Oncologie. 1 sept, vol.5, issue.5, pp.267-74, 2019.

M. M. Oken, R. H. Creech, D. C. Tormey, J. Horton, T. E. Davis et al., Toxicity and response criteria of the Eastern Cooperative Oncology Group, AMERICAN JOURNAL OF CLINICAL ONCOLOGY. déc, vol.5, issue.6, pp.649-56, 1982.

T. Perez, M. Montaleytang, C. Boisseranc, D. Crozals, F. Darbon et al., Retour d'expérience en pharmacie clinique oncologique, Annales Pharmaceutiques Françaises. janv, vol.78, issue.1, pp.70-75, 2020.

R. Boulkedid, H. Abdoul, M. Loustau, O. Sibony, and C. Alberti, Using and Reporting the Delphi Method for Selecting Healthcare Quality Indicators: A Systematic Review, PLOS ONE. 9 juin, vol.6, issue.6, p.20476, 2011.

, Élaboration de recommandations de bonne pratique -Méthode « Recommandations par consensus formalisé, HAS, 2010.

D. Sur,

M. E. Charlson, P. Pompei, K. L. Ales, and C. R. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation, Journal of Chronic Diseases. janv, vol.40, issue.5, pp.373-83, 1987.

, Common Terminology Criteria for Adverse Events (CTCAE)

G. Guthrie, K. A. Charles, C. Roxburgh, P. G. Horgan, D. C. Mcmillan et al., The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer, Critical Reviews in Oncology/Hematology. oct, vol.88, issue.1, pp.218-248, 2013.

A. Ribed, R. M. Romero-jiménez, V. Escudero-vilaplana, I. Iglesias-peinado, A. Herranz-alonso et al., Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction, Int J Clin Pharm. avr, vol.38, issue.2, pp.280-288, 2016.

V. Cristina, J. Mahachie, M. Mauer, T. Buclin, E. Van-cutsem et al., Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group, JAMA Oncol. 1 juill, vol.4, issue.7, p.1003, 2018.

O. Abdel-rahman, Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials, Clinical Colorectal Cancer. 1 juin, vol.18, issue.2, pp.110-115, 2019.

O. Schmetzer and A. Flörcken, Sex Differences in the Drug Therapy for Oncologic Diseases, Regitz-Zagrosek V, éditeur. Sex and Gender Differences in Pharmacology

H. Berlin, Disponible sur, vol.214, pp.411-453, 2013.

T. Bachelot, I. Ray-coquard, G. Catimel, C. Ardiet, J. P. Guastalla et al., Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials, Annals of Oncology. févr, vol.11, issue.2, pp.151-157, 2000.

R. W. Jang, V. B. Caraiscos, N. Swami, S. Banerjee, E. Mak et al., Simple Prognostic Model for Patients With Advanced Cancer Based on Performance Status, JOP. 12 août, vol.10, issue.5, pp.335-376, 2014.

M. Ando, Y. Ando, Y. Hasegawa, K. Shimokata, H. Minami et al., Prognostic value of performance status assessed by patients themselves, nurses and oncologists in advanced non-small cell lung cancer, Br J Cancer. déc, vol.85, issue.11, pp.1634-1643, 2001.

G. Popovic, T. Harhara, A. Pope, A. Awamer, S. Banerjee et al., Patient-Reported Functional Status in Outpatients With Advanced Cancer: Correlation With Physician-Reported Scores and Survival, Journal of Pain and Symptom Management. juin, vol.55, issue.6, pp.1500-1508, 2018.

Q. Zhao, Y. Yang, S. Xu, X. Zhang, H. Wang et al., Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patients, Onco Targets Ther, vol.8, pp.2731-2739, 2015.

M. Rivas, F. Acevedo, F. Dominguez, H. Galindo, M. Camus et al., The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer, Asian Pac J Cancer Prev. 1 juill, vol.20, issue.7, pp.2209-2221, 2019.

T. T. Yeoh, X. Y. Tay, P. Si, and L. Chew, Drug-related problems in elderly patients with cancer receiving outpatient chemotherapy, Journal of Geriatric Oncology. juill, vol.6, issue.4, pp.280-287, 2015.

D. Sarfati, B. Koczwara, and C. Jackson, The impact of comorbidity on cancer and its treatment: Cancer and Comorbidity, CA: A Cancer Journal for Clinicians. juill, vol.66, issue.4, pp.337-50, 2016.

R. Van-leeuwen, D. Brundel, C. Neef, T. Van-gelder, R. Mathijssen et al., Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs, Br J Cancer. mars, vol.108, issue.5, pp.1071-1079, 2013.

N. White, F. Reid, A. Harris, P. Harries, and P. Stone, A Systematic Review of Predictions of Survival in Palliative Care: How Accurate Are Clinicians and Who Are the Experts?, Thompson Coon J, éditeur. PLoS ONE. 25 août, vol.11, issue.8, p.161407, 2016.

J. M. Jacobs, M. E. Ream, N. Pensak, L. E. Nisotel, J. N. Fishbein et al., Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of Life, Journal of the National Comprehensive Cancer Network. 11 mars, vol.17, issue.3, pp.221-229, 2019.

F. Dalenc, Toxicité et effets secondaires à long terme de l'hormonothérapie adjuvante -Sequels after hormonal treatment for breast cancer, La Lettre du Sénologue. juin, issue.44, p.5, 2009.

A. De-la-taille, S. Drouin, M. Rouprêt, P. Perrin, and M. Zerbib, Étude observationnelle CAPITAL et prescription de l'hormonotherapie par les urologues français dans la pratique quotidienne, Progrès en Urologie. avr, vol.19, pp.20-25, 2009.